The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Takeda Faces New Problem on Leuplin, System Glitch Cripples Supply of 1, 3-Month Products
Takeda Pharmaceutical has stumbled on another problem over its cancer drug Leuplin (leuprorelin), which has been subject to shipment restrictions since last year following GMP issues, with a glitch in its manufacturing system stalling the supply of some products. The…
To read the full story
Related Article
- Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
- Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
- Japan Sees Improved LHRH Agonist Supply as Leuprorelin Output Rises; Shipment Curbs for Substitutes Lifted
October 15, 2020
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…